MCID: PPT001
MIFTS: 47

Peptic Esophagitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Esophagitis

MalaCards integrated aliases for Peptic Esophagitis:

Name: Peptic Esophagitis 12 15 17 72
Reflux Esophagitis 12 75 15
Gastro-Esophageal Reflux Disease with Esophagitis 72
Peptic Reflux Disease 12
Reflux Oesophagitis 12
Esophagitis, Peptic 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13976
ICD9CM 35 530.11
MeSH 44 D004942
SNOMED-CT 68 54856001 57643001
UMLS 72 C0014869 C0677659

Summaries for Peptic Esophagitis

MalaCards based summary : Peptic Esophagitis, also known as reflux esophagitis, is related to bile reflux and hernia, hiatus. An important gene associated with Peptic Esophagitis is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Legionellosis and Malaria. The drugs Esomeprazole and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and heart.

Wikipedia : 75 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition in which... more...

Related Diseases for Peptic Esophagitis

Diseases related to Peptic Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 bile reflux 31.5 ATP4A ATP12A
2 hernia, hiatus 31.1 CYP2C19 ATP4A ATP12A
3 esophageal varix 31.0 ATP4A ATP12A
4 microinvasive gastric cancer 30.9 ATP4A ATP12A
5 esophagitis 30.7 IL1B HRH2 CYP2C19 CXCL8
6 dyskinesia of esophagus 30.6 ATP4A ATP12A
7 dyspepsia 30.6 HRH2 CYP2C19 CXCL8
8 duodenitis 30.6 ATP4A ATP12A
9 esophagus adenocarcinoma 30.5 ATP4A ATP12A
10 atrophic gastritis 30.5 IL1B CXCL8
11 superior mesenteric artery syndrome 30.5 ATP4A ATP12A
12 peptic ulcer perforation 30.2 HRH2 ATP4A ATP12A
13 esophageal disease 30.1 HRH2 ATP4A ATP12A
14 active peptic ulcer disease 30.1 HRH2 ATP4A ATP12A
15 esophageal candidiasis 30.1 CYP2C19 ATP4A ATP12A
16 gastroesophageal reflux 30.0 IL1B HRH2 CYP2C19 CXCL8
17 pharyngitis 30.0 IL1B CXCL8
18 esophagitis, eosinophilic, 1 29.9 EPC2 ATP4A ATP12A
19 gastrointestinal system disease 29.9 IL1B CXCL8 ATP4A ATP12A
20 gastritis 29.7 IL1B HRH2 CXCL8
21 tonsillitis 29.6 IL1B CXCL8
22 laryngitis 29.5 IL1B HRH2 ATP4A ATP12A
23 duodenal ulcer 29.4 IL1B HRH2 CYP2C19 CXCL8
24 helicobacter pylori infection 29.4 IL1B CYP2C19 CXCL8
25 peptic ulcer disease 29.0 IL1B HRH2 CYP2C19 CXCL8 ATP4A
26 gastric ulcer 28.9 IL1B HRH2 CYP2C19 CXCL8
27 sandifer syndrome 11.4
28 duodenal atresia 11.3
29 gastroparesis 11.3
30 fungal esophagitis 10.6 ATP4A ATP12A
31 gastroduodenal crohn's disease 10.6 ATP4A ATP12A
32 diclofenac allergy 10.6 ATP4A ATP12A
33 neonatal candidiasis 10.6 ATP4A ATP12A
34 squamous papillomatosis 10.6 ATP4A ATP12A
35 photoallergic dermatitis 10.6 ATP4A ATP12A
36 gastrointestinal neuroendocrine benign tumor 10.6 ATP4A ATP12A
37 toxic megacolon 10.6 ATP4A ATP12A
38 granulomatous gastritis 10.6 ATP4A ATP12A
39 gastric antral vascular ectasia 10.6 ATP4A ATP12A
40 acute laryngitis 10.6 ATP4A ATP12A
41 gastric neuroendocrine neoplasm 10.6 ATP4A ATP12A
42 rumination disorder 10.6 ATP4A ATP12A
43 capillary disease 10.6 ATP4A ATP12A
44 ischemic neuropathy 10.6 ATP4A ATP12A
45 bladder calculus 10.6 ATP4A ATP12A
46 congenital disorder of deglycosylation 10.6 ATP4A ATP12A
47 anismus 10.6 ATP4A ATP12A
48 postsurgical hypothyroidism 10.6 ATP4A ATP12A
49 esophageal atresia/tracheoesophageal fistula 10.5 ATP4A ATP12A
50 lymphocytic colitis 10.5 ATP4A ATP12A

Comorbidity relations with Peptic Esophagitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Bronchitis
Deficiency Anemia Esophageal Disease
Esophagitis Gastroesophageal Reflux
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Peptic Esophagitis:



Diseases related to Peptic Esophagitis

Symptoms & Phenotypes for Peptic Esophagitis

Drugs & Therapeutics for Peptic Esophagitis

Drugs for Peptic Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Famotidine Approved Phase 4 76824-35-6 3325
4
Trimebutine Approved Phase 4 39133-31-8
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
8
Ondansetron Approved Phase 4 99614-02-5 4595
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
11
Calcium polycarbophil Approved Phase 4 126040-58-2
12
Ethanol Approved Phase 4 64-17-5 702
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Prucalopride Approved Phase 4 179474-81-8
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
17
Lithium carbonate Approved Phase 4 554-13-2
18
Clozapine Approved Phase 4 5786-21-0 2818
19
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
20
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
21
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
22
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
23
Ziprasidone Approved Phase 4 146939-27-7 60854
24
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
25
Clarithromycin Approved Phase 4 81103-11-9 84029
26
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
27
Pantoprazole Approved Phase 4 102625-70-7 4679
28
Citalopram Approved Phase 4 59729-33-8 2771
29
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
30 Ramosetron Investigational Phase 4 132036-88-5
31 Rebamipide Investigational Phase 4 90098-04-7
32 Mosapride Investigational Phase 4 112885-41-3
33
Polaprezinc Experimental Phase 4 107667-60-7
34 Histamine Antagonists Phase 4
35 Histamine H2 Antagonists Phase 4
36
Histamine Phosphate Phase 4 51-74-1 65513
37 Antioxidants Phase 4
38 Protective Agents Phase 4
39 Hormone Antagonists Phase 4
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
41 Anti-Inflammatory Agents Phase 4
42 glucocorticoids Phase 4
43 Acidophilus Phase 4
44 Central Nervous System Depressants Phase 4
45 Tranquilizing Agents Phase 4
46 HIV Protease Inhibitors Phase 4
47
protease inhibitors Phase 4
48 Analgesics Phase 4
49 Analgesics, Non-Narcotic Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 477)
# Name Status NCT ID Phase Drugs
1 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
2 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
3 Effectiveness of Lactobacillus GG in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children With Gastroesophageal Reflux Disease Treated With Proton Pump Inhibitors: Randomized Double - Blind Placebo, Controlled Trial. Unknown status NCT01782118 Phase 4
4 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
5 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
6 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
7 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
8 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
9 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
10 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
11 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
12 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
13 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
14 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
15 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
16 Aflurax Versus Nexium Given on Demand to Patients With Gastro-esophageal Reflux Disease. Completed NCT00184522 Phase 4 Aflurax;esomeprazole
17 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
18 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study Completed NCT01135368 Phase 4 Lansoprazole
19 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
20 A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy Completed NCT00637845 Phase 4 Esomeprazole Magnesium;Lansoprazole
21 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
22 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
23 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
24 A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks. Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
25 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
27 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
28 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
29 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
30 A Pilot Study Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole 60 mg and Esomeprazole 40 mg for Gastroesophageal Reflux Disease Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
31 Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD) Completed NCT00574925 Phase 4 Esomeprazole
32 The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia. Completed NCT00287391 Phase 4 Rabeprazole
33 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
34 Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD Completed NCT00304421 Phase 4 rabeprazole;pantoprazole
35 Effect of Citalopram on Fasting and Postprandial Lower Esophageal Sphincter Function in Healthy Subjects: a Double-blind, Placebo-controlled, Randomized, Cross-over Study Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
36 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
37 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
38 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
39 RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Completed NCT01503476 Phase 4
40 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
41 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
42 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
43 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
44 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
45 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
46 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
47 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
48 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
49 Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
50 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg

Search NIH Clinical Center for Peptic Esophagitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Calcium Glycerophosphate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Famotidine
Magnesium Hydroxide
MILK OF MAGNESIA
Nizatidine

Cochrane evidence based reviews: esophagitis, peptic

Genetic Tests for Peptic Esophagitis

Anatomical Context for Peptic Esophagitis

MalaCards organs/tissues related to Peptic Esophagitis:

41
Testes, Colon, Heart, Lung, Liver, Bone, Smooth Muscle

Publications for Peptic Esophagitis

Articles related to Peptic Esophagitis:

(show top 50) (show all 3560)
# Title Authors PMID Year
1
Clinical prediction model for tumor progression in Barrett's esophagus. 38
30456503 2019
2
Surgical outcomes and risk assessment for anastomotic complications after laparoscopic proximal gastrectomy with double-flap technique for upper-third gastric cancer. 38
30838469 2019
3
Esophagitis in Pediatric Esophageal Atresia: Acid May Not Always Be the Issue. 38
30921254 2019
4
Efficacy of Celiac Branch Preservation in Billroth-Ⅰ Reconstruction After Laparoscopy-Assisted Distal Gastrectomy. 38
31425872 2019
5
Another Case of Reflux Esophagitis? 38
30965028 2019
6
Changes in Clock Genes Expression in Esophagus in Rat Reflux Esophagitis. 38
30815822 2019
7
Laparoscopic Roux-en-Y Gastric Bypass After Gastroesophageal Reflux Disease Surgical Procedure: Analysis of 85 Consecutive Patients with Pre- and Post-Operative Endoscopy Control. 38
31368842 2019
8
An Operable, Portable, and Disposable Ultrathin Endoscope for Evaluation of the Upper Gastrointestinal Tract. 38
30684078 2019
9
Kamikawa Double-Flap Reconstruction After Minimally Invasive Ivor-Lewis Esophagectomy. 38
30872101 2019
10
A population-based survey of gastroesophageal reflux disease in a region with high prevalence of esophageal cancer in China. 38
31045906 2019
11
Activin A-mediated epithelial de-differentiation contributes to injury repair in an in vitro gastrointestinal reflux model. 38
31369967 2019
12
Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial. 38
31287522 2019
13
Update on Endoscopic Approaches for the Management of Gastroesophageal Reflux Disease. 38
31391807 2019
14
Gender Specific Differences in Prevalence and Risk Factors for Gastro-Esophageal Reflux Disease. 38
31144481 2019
15
Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. 38
31240437 2019
16
Risks of substance uses, alcohol flush response, Helicobacter pylori infection and upper digestive tract diseases-An endoscopy cross-sectional study. 38
31001924 2019
17
The impact of cervical lymph node dissection on acid and duodenogastroesophageal reflux after intrathoracic esophagogastrostomy following transthoracic esophagectomy. 38
31218418 2019
18
The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study. 38
30970442 2019
19
Cudrania tricuspidata Extract Protects against Reflux Esophagitis by Blocking H2 Histamine Receptors. 38
31328120 2019
20
Esophageal A-ring is associated with the severity of gastroesophageal reflux. 38
31199518 2019
21
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. 38
31178490 2019
22
Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis. 38
31276037 2019
23
Esophageal IgG4: Clinical, Endoscopic, and Histologic Correlations in Eosinophilic Esophagitis. 38
30540707 2019
24
Proximal versus total gastrectomy for proximal early gastric cancer: A systematic review and meta-analysis. 38
31083268 2019
25
[Comparison of safety and efficacy between proximal gastrectomy and total gastrectomy for upper third gastric cancer: a Meta-analysis]. 38
31104433 2019
26
Long-term effect of Helicobacter pylori eradication on prevalence of reflux esophagitis. 38
31111517 2019
27
Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial. 38
31114137 2019
28
Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis. 38
31129668 2019
29
Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. 38
31119492 2019
30
Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users. 38
31086661 2019
31
Radiofrequency ablation is safe and effective in the treatment of Chinese patients with gastroesophageal reflux disease: A single-center prospective study. 38
30873743 2019
32
Comparison of Hemospray® and Endoclot™ for the treatment of gastrointestinal bleeding. 38
30983819 2019
33
Detachable string magnetically controlled capsule endoscopy for complete viewing of the esophagus and stomach. 38
30822803 2019
34
Barrett's esophagus is negatively associated with eosinophilic esophagitis in Japanese subjects. 38
30327893 2019
35
Surgical outcomes and over one-year follow-up results of laparoscopic Nissen fundoplication for gastroesophageal reflux disease: Single-center experiences. 38
30316665 2019
36
Chronic Obstructive Pulmonary Disease and the Risk of Esophagitis, Barrett Esophagus, and Esophageal Adenocarcinoma: A Primary Care Case-Control Study. 38
31008868 2019
37
History of gastroesophageal reflux disease in patients with suspected coronary artery disease. 38
30993440 2019
38
Laparoscopic One Anastomosis Gastric Bypass Versus Laparoscopic One Anastomosis Gastric Bypass with Braun Anastomosis: What's Better? 38
31017503 2019
39
An association of Helicobacter pylori infection with endoscopic and histological findings in the Nepalese population. 38
31041278 2019
40
Curcumin: A Potent Protectant against Esophageal and Gastric Disorders. 38
30909623 2019
41
[A Case in Which Acotiamide Hydrochloride Was Effective for Reflux Esophagitis after Distal Gastrectomy with Billroth Ⅰ Reconstruction for Gastric Cancer]. 38
30914625 2019
42
[CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF THE GASTRODUODENAL MUCOSAL LESIONS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION WITH DIFFERENT BODY MASS STATUS]. 38
31101780 2019
43
Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease. 38
30465175 2019
44
Long-Term Efficacy of Peroral Endoscopic Myotomy for Patients with Achalasia: Outcomes with a Median Follow-Up of 36 Months. 38
30478767 2019
45
Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis. 38
30921053 2019
46
What is the impact of metabolic syndrome and its components on reflux esophagitis? A cross-sectional study. 38
30782138 2019
47
Esophagogastric junction outflow obstruction successfully treated with laparoscopic Heller myotomy and Dor fundoplication: First case report in the literature. 38
30842817 2019
48
[Surgical strategy for adenocarcinoma of esophagogastric junction]. 38
30799532 2019
49
[Clinical study on two reconstruction methods of proximal gastrectomy and piggyback jejunal interposition for Siewert Ⅱ or Ⅲ adenocarcinoma of esophagogastric junction]. 38
30704214 2019
50
An update on the latest chemical therapies for reflux esophagitis in children. 38
30496693 2019

Variations for Peptic Esophagitis

Expression for Peptic Esophagitis

Search GEO for disease gene expression data for Peptic Esophagitis.

Pathways for Peptic Esophagitis

Pathways related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.07 IL1B CXCL8
2 10.95 IL1B CXCL8
3 10.85 IL1B CXCL8
4 10.62 HRH2 ATP4A
5 9.32 HRH2 ATP4A

GO Terms for Peptic Esophagitis

Biological processes related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import across plasma membrane GO:1990573 9.4 ATP4A ATP12A
2 ATP hydrolysis coupled proton transport GO:0015991 9.37 ATP4A ATP12A
3 cellular sodium ion homeostasis GO:0006883 9.26 ATP4A ATP12A
4 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP4A ATP12A
5 positive regulation of neutrophil chemotaxis GO:0090023 9.02 CXCL8
6 sodium ion export across plasma membrane GO:0036376 8.96 ATP4A ATP12A
7 cellular potassium ion homeostasis GO:0030007 8.62 ATP4A ATP12A

Molecular functions related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP4A ATP12A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP4A ATP12A

Sources for Peptic Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....